Exploratory test on the influence of kestose intake on lifestyle-related diseases improvement effect

Exploratory test on the influence of kestose intake on lifestyle-related diseases improvement effect - Exploratory test on the influence of kestose intake on lifestyle-related diseases improvement effect

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028824

Enrollment

Registered

2017-08-25

Start date

2017-09-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Adults

Interventions

Ingest total 10 g of kestose, 5 g each in the morning and the night. Ingest total 10 g of maltose, 5 g each in the morning and the night.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Persons who received a sufficient explanation of the purpose and contents of the exam, have the capacity to consent, applied with free will with sufficient understanding, and agreed to participate with a written document 2.Healthy Japanese who is 20 years old or more and under 64 years old 3.Persons whose BMI is 23 or more at screening

Exclusion criteria

Exclusion criteria: 1.Persons who have a chronic disease and is under medication, or has a serious disease history 2.Persons whose HOMA-IR at screening is 2.5 or more 3.Persons whose fasting blood glucose level at screening is 126 mg/dL or more 4.Persons whose LDL cholesterol at screening is 140 mg/dL or more 5.Persons whose blood neutral fat at screening is 150 mg/dL or more 6.Persons who are allergic to the test food 7.Persons who participated in other examination during the first month before the start of the exam, or those who plan to participate in other exams following this exam agreement 8.Persons who are breastfeeding, pregnant, scheduled or hoping to be pregnant during the exam period 9.Persons who are judged inappropriate for the exam by the principal investigator

Design outcomes

Primary

Measure	Time frame
Insulin resistance (glucose, HbA1c, insulin, HOMA-IR, AUC, Cmax, C, myoinositol, creatinine) at the beginning of the test or after ingestion of 4, 8 and 12 weeks	—

Secondary

Measure	Time frame
Cholesterol (total cholesterol, LDL-cholesterol), blood neutral fat (TG), general blood biochemical test (HDL-cholesterol, AST, ALT, g-GT, urea nitrogen, creatinine , TNF-a, IL-1b, IL-6, IL-10, BDNF), intestinal environment (urine, albumin, total protein, ALP, LD, sodium, chlorine, potassium, calcium, inorganic phosphorus, magnesium, free fatty acid, (indoxyl sulfate, creatinine, short chain fatty acid, intestinal bacteria), stress (IgA), physical examination (body weight, blood pressure, pulse rate, BMI), questionnaire, at the beginning of the test or after ingestion of 4, 8 and 12 weeks	—

Measure

Time frame

Cholesterol (total cholesterol, LDL-cholesterol), blood neutral fat (TG), general blood biochemical test (HDL-cholesterol, AST, ALT, g-GT, urea nitrogen, creatinine , TNF-a, IL-1b, IL-6, IL-10, BDNF), intestinal environment (urine, albumin, total protein, ALP, LD, sodium, chlorine, potassium, calcium, inorganic phosphorus, magnesium, free fatty acid, (indoxyl sulfate, creatinine, short chain fatty acid, intestinal bacteria), stress (IgA), physical examination (body weight, blood pressure, pulse rate, BMI), questionnaire, at the beginning of the test or after ingestion of 4, 8 and 12 weeks

—

Countries

Japan

Contacts

Public ContactHirohito Ishikawa

Healthcare Systems Co., Ltd. Research and Development

ishikawa@hc-sys.jp0368092722

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026